or Try an Advanced Search...

    Technical Analysis for ZURA - Zura Bio Limited

    Grade Last Price % Change Price Change
    F 3.63 3.71% 0.13
    ZURA closed up 3.71 percent on Monday, July 1, 2024, on 2.31 times normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical ZURA trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Wide Bands Range Expansion 0.00%
    Up 3 Days in a Row Strength 0.00%
    Golden Cross Bullish 3.71%
    Pocket Pivot Bullish Swing Setup 3.71%
    Wide Bands Range Expansion 3.71%
    Oversold Stochastic Weakness 3.71%
    NR7 Range Contraction 7.72%
    Older End-of-Day Signals for ZURA ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 20 DMA about 8 hours ago
    2x Volume Pace about 8 hours ago
    Possible Pocket Pivot about 8 hours ago
    Up 10% about 8 hours ago
    Up 1 ATR about 8 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ZURA Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Zura is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Immunology Diabetes Monoclonal Antibody Antibody

    Is ZURA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 14 Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
    Jun 6 Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
    Jun 3 Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
    May 29 Zura Bio Announces Participation in June Investor Conferences
    May 24 Zura Bio files to sell 41.6M Class A ordinary shares for holders
    May 10 Zura Bio Ltd (ZURA) Q1 2024 Earnings: Financial and Strategic Developments
    May 9 Zura Bio reports Q1 results
    May 9 Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
    Apr 25 Director Amit Munshi Acquires 159,744 Shares of Zura Bio Ltd (ZURA)
    Apr 18 Zura Bio stock jumps on plans to raise $112.5M in private financing
    See more ZURA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 8.25
    52 Week Low 2.0
    Average Volume 201,146
    200-Day Moving Average 4.34
    50-Day Moving Average 4.37
    20-Day Moving Average 3.77
    10-Day Moving Average 3.45
    Average True Range 0.36
    RSI (14) 41.86
    ADX 23.36
    +DI 21.06
    -DI 19.16
    Chandelier Exit (Long, 3 ATRs) 4.49
    Chandelier Exit (Short, 3 ATRs) 4.21
    Upper Bollinger Bands 4.64
    Lower Bollinger Band 2.91
    Percent B (%b) 0.42
    BandWidth 45.92
    MACD Line -0.31
    MACD Signal Line -0.31
    MACD Histogram -0.0067
    Fundamentals Value
    Market Cap 156.43 Million
    Num Shares 43.1 Million
    EPS 0.15
    Price-to-Earnings (P/E) Ratio 24.20
    Price-to-Sales 0.00
    Price-to-Book 2.67
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.38
    Resistance 3 (R3) 4.39 4.16 4.26
    Resistance 2 (R2) 4.16 3.97 4.15 4.21
    Resistance 1 (R1) 3.89 3.85 4.03 3.88 4.17
    Pivot Point 3.66 3.66 3.72 3.65 3.66
    Support 1 (S1) 3.39 3.47 3.53 3.38 3.09
    Support 2 (S2) 3.16 3.35 3.15 3.05
    Support 3 (S3) 2.89 3.16 3.01
    Support 4 (S4) 2.88